IN8bio, Inc.
INAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,104 | $2,487 | $2,972 | $3,594 |
| G&A Expenses | $1,863 | $2,714 | $2,688 | $2,630 |
| SG&A Expenses | $1,863 | $2,714 | $2,688 | $2,630 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$113 | -$107 | -$110 | -$64 |
| Operating Expenses | $3,854 | $5,094 | $5,550 | $6,160 |
| Operating Income | -$3,854 | -$5,094 | -$5,550 | -$6,160 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$3,854 | -$5,094 | -$5,550 | -$6,160 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,854 | -$5,094 | -$5,550 | -$6,160 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -1.24 | -0.067 | -0.085 |
| % Growth | 31.5% | -1,764.7% | 21.8% | – |
| EPS Diluted | -0.85 | -1.24 | -0.067 | -0.085 |
| Weighted Avg Shares Out | 4,538 | 4,119 | 83,482 | 56,674 |
| Weighted Avg Shares Out Dil | 4,538 | 4,119 | 83,482 | 56,674 |
| Supplemental Information | – | – | – | – |
| Interest Income | $113 | $107 | $110 | $64 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $527 | $784 | $669 | $702 |
| EBITDA | -$3,327 | -$4,417 | -$4,991 | -$5,522 |
| % Margin | – | – | – | – |